TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 150 filers reported holding TRAVERE THERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is 0.84 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $128,441 | -41.5% | 14,367 | +0.5% | 0.00% | -100.0% |
| Q2 2023 | $219,664 | -16.7% | 14,301 | +21.9% | 0.00% | 0.0% |
| Q1 2023 | $263,830 | -5.1% | 11,731 | -11.3% | 0.00% | 0.0% |
| Q4 2022 | $278,143 | -6.7% | 13,226 | +9.4% | 0.00% | 0.0% |
| Q3 2022 | $298,000 | +4.6% | 12,094 | +2.6% | 0.00% | 0.0% |
| Q2 2022 | $285,000 | -37.2% | 11,788 | -33.1% | 0.00% | 0.0% |
| Q1 2022 | $454,000 | -32.1% | 17,632 | -18.1% | 0.00% | 0.0% |
| Q4 2021 | $669,000 | +34.9% | 21,523 | +5.3% | 0.00% | 0.0% |
| Q3 2021 | $496,000 | +30.9% | 20,438 | -21.4% | 0.00% | 0.0% |
| Q2 2021 | $379,000 | -33.3% | 25,987 | +14.2% | 0.00% | -50.0% |
| Q1 2021 | $568,000 | +11.4% | 22,756 | +21.6% | 0.00% | 0.0% |
| Q4 2020 | $510,000 | – | 18,718 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 895,821 | $8,008,640 | 3.99% |
| Deep Track Capital, LP | 7,370,000 | $65,887,800 | 2.54% |
| VR Adviser, LLC | 2,623,677 | $23,455,672 | 2.47% |
| Sio Capital Management, LLC | 884,770 | $7,909,844 | 2.45% |
| Kynam Capital Management, LP | 957,502 | $8,560,068 | 1.40% |
| MPM BioImpact LLC | 552,846 | $4,942,443 | 1.32% |
| ARMISTICE CAPITAL, LLC | 7,500,000 | $67,050,000 | 1.03% |
| Parkman Healthcare Partners LLC | 577,494 | $5,162,796 | 0.95% |
| Tri Locum Partners LP | 251,702 | $2,250,216 | 0.72% |
| Cheyne Capital Management (UK) LLP | 26,200 | $234,228 | 0.68% |